HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 -- HUTCHMED Limited ; class='js-l-obf link link--blue'

Related Keywords

Australia ,Hong Kong ,Japan ,Shanghai ,China ,Panmure ,Victoria ,Ben Atwell Alex Shaw ,Annie Cheng ,Mark Lee ,Zhou Yi ,Eli Lilly ,Stock Exchange Of Hong Kong ,Drug Administration ,Exchange Commission ,Linkedin ,National Reimbursement Drug List ,Devices Agency ,Nasdaq ,Innovent Biologics Inc ,European Medicines Agency ,China Limited ,Japan Pharmaceuticals ,Takeda Pharmaceutical Company ,Drug Evaluation ,National Medical Products Administration ,Breakthrough Therapy Designation ,New Drug Application ,Prescription Drug User Fee Act ,Medical Devices Agency ,Takeda Pharmaceutical Company Limited ,Innovent Biologics ,Securities Litigation Reform Act ,Stock Exchange ,Senior Vice ,Brad Miles ,Ben Atwell ,Alex Shaw ,Freddy Crossley ,Daphne Zhang ,Mismatch Repair ,Global Cancer Observatory ,World Fact ,Accessed June ,China Fact ,Practice Guidelines ,Markets ,